NCT01832857 2016-12-29Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer PatientsCornerstone PharmaceuticalsPhase 2 Terminated7 enrolled
NCT01830322 2013-08-14Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic Pancreatic CancerCornerstone PharmaceuticalsPhase 2 Withdrawn